Open AccessP534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST‐LINE AML PATIENTS
Author(s) -
Garciaz S.,
Hospital M.A.,
Alary A.S.,
Saillard C.,
Hicheri Y.,
Mohty B.,
Rey J.,
D'incan E.,
Charbonnier A.,
Ferdinand V.,
Maisano V.,
Lombardi L.,
Ittel A.,
Mozziconacci M.J.,
GelsiBoyer V.,
Vey N.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845024.01860.8d
Subject(s) - venetoclax , ven , azacitidine , medicine , concomitant , hypomethylating agent , oncology , refractory (planetary science) , leukemia , gastroenterology , chronic lymphocytic leukemia , biology , gene expression , dna methylation , gene , biochemistry , computer security , computer science , astrobiology